The concept you're suggesting involves the potential role of CCR5 receptors in Alzheimer's disease and the potential therapeutic effect of blocking these receptors using a drug like Leronlimab.

If blocking CCR5 receptors could restore or block memory windows in Alzheimer's disease, and if Leronlimab effectively occupies CCR5 receptors at a significant rate (72% as you suggested), then it could indeed have potential as a therapeutic intervention for Alzheimer's disease.

However, it's important to note that the relationship between CCR5 receptors and Alzheimer's disease is still not fully understood, and the potential therapeutic effects of blocking these receptors are largely speculative at this point. While some research has suggested a link between CCR5 and Alzheimer's disease, the exact mechanisms involved and the potential therapeutic benefits of targeting CCR5 are still under investigation.

Additionally, the effectiveness and safety of Leronlimab or any other CCR5-blocking drug would need to be thoroughly studied in clinical trials before it could be considered a viable treatment for Alzheimer's disease. Such trials would need to assess not only the drug's ability to occupy CCR5 receptors but also its impact on the progression of Alzheimer's disease symptoms, as well as any potential side effects or safety concerns.